Table 1.

Baseline and time-updated characteristics of cases and controls.

	Cases (n = 41)	Controls (n = 111)	P-value
Age (years), med (IQR)	44 (33, 49)	37 (30, 43)	0.04
Female, n (%)	14 (34)	13 (12)	0.003
Race/Ethnicity, n (%)			0.25
White	21 (51)	46 (41)
Black	9 (22)	42 (38)
Hispanic	9 (22)	21 (19)
Other	2 (5)	2 (2)
Hepatitis C Seropositive, n (%)§	2 (9)	9 (12)
Study Week (Time to a new AIDS-defining event or death after HAART-initiation), med (IQR)	12 (5, 53)	–
Baseline values: med (IQR)
CD4 cells, per mm3	42 (17, 176)	62 (20, 222)	0.32
HIV-RNA, log10 copies/mL	5.51 (4.88, 6.02)	5.40 (4.67, 6.04)	0.75
Hemoglobin, Gm/dL	11.9 (10.4, 13.7)	12.0 (11.9, 13.8)	0.01
%CD8+/HLA-DR+/CD38+	56 (44, 63)	50 (40, 62)	0.08
sTNFR-I, pg/mL	1423(1215, 1789)	1175 (902, 1487)	0.001
sTNFR-II, ng/mL	8.42(6.72, 12.9)	7.47(4.85, 10.33)	0.06
sCD27, U/mL	420 (304, 653)	304 (230, 448)	0.007
sCD40L, ng/mL	0.72 (0.36, 1.13)	0.52 (0.24, 0.93)	0.14
sTRAIL, pg/mL	449 (309, 639)	504 (349, 715)	0.31
IL-6, pg/mL	3.13 (1.77, 4.78)	1.48 (1.02, 3.10)	0.002
Time updated values at the onset of an AIDS defining illness or death, med (IQR)
CD4 cell count, per mm3	66 (17, 236)	145 (25, 366)	0.07
HIV-RNA, log10 cop/mL	2.89 (1.69, 5.67)	2.58 (1.69, 5.37)	0.39
HIV-RNA < 200 cop/mL, n (%)	50 (45)	18 (44)	1.0
HIV-RNA < 50 cop/mL, n (%)	12 (29)	40 (36)	0.56
%CD8+/HLA-DR+/CD38+	44 (36, 57)	39 (25, 52)	0.07

Time-updated values among cases indicate the latest, antecedent values before a clinical event; for control subjects values from the same study week, or the closest antecedent study week to that of their corresponding case were used. The significance of differences between cases and controls are indicated by:

^***=p<0.001;

^**=p<0.05 and p ≥ 0.001;

^*= p < 0.10 and p ≥ 0.05.

^§HCV-serostatus was available in 23 cases and 75 controls.